Aurobindo Pharma - walk in interview for Production, QC, IPQA, QMS, Validations
About Aurobindo Pharma:-
Aurobindo Pharma Limited is a Pharmaceutical Manufacturing Company which is located in HITEC City, Headquarter, India, Hyderabad. The company prepares generic pharmaceuticals and active pharmaceutical ingredients. There are six major therapeutic / manufacturing areas in the company's activity area: Antibiotics, Anti-Retroviral, Cardiovascular Products, Central Nervous System Products, Gastroenterology, and Anti-Allergy. The company brings these products to more than 125 countries. Among its marketing partners, AstraZeneca and Pfizer are included.
In 1988-89, the company started the operation of a single unit product in Puducherry with semi-synthetic penicillin (SSP). Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock market in 1995. Aurobindo Pharma is also present in major therapeutic segments like neurosciences, cardiovascular, anti-retroviral, anti-diabetics, gastroenterology, and cephalosporin.
Aurobindo Pharma is featured as the combined revenue of the top 10 companies in India. Exports of Aurobindo to more than 125 countries worldwide and more than 70% of earnings are earned through international conventions.
In 2014, Aurobindo bought $ 41 million of operating operations in 7 Western European countries.
Aurobindo pharma business expansion:-
Aurobindo Pharma is planning to expand product innovation oncology, hormones, biosimilars, and new medicinal distribution solutions such as injection, inhalers, patches, and films with high-value products. These countries have also made general passes on geographical extensions of new areas such as Poland, Italy, Spain, the Czech Republic, Portugal, and France.
In 2017, the Aurobindo Pharma signed an agreement to buy Portugal's generic farm-city SA from Magnum Capital Partners, which was considered € 135 million. He also bought four biosimilar products from Swiss firm TL Biopharmaceutical AG.
Aurobindo Pharma Limited made a definite agreement to buy Apotex Business in Poland, Czech Republic, Netherlands, Spain, and Belgium. The contract is conditional after the competition is approved by Dutch and Polish authorities. As part of the proposed sale, Apotex will enter into a transitional production and supply system with Aurobindo to support the ongoing growth plans of the business.
